v3.26.3
Stock-Based Compensation
9 Months Ended
Sep. 30, 2026
Stock-Based Compensation  
Stock-Based Compensation

(11)  Stock-Based Compensation

A summary of stock option activity for the nine months ended September 30, 2026 is as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

Weighted

​

​

​

​

Average

​

Average

​

​

​

​

Exercise

​

Remaining

​

​

​

​

Price

​

Contractual

​

  ​ ​ ​

Shares

  ​ ​ ​

Per Share

  ​ ​ ​

Term (In Years)

Options outstanding at December 31, 2025

 

9,134,278

​

$

26.49

​

7.1

Granted

 

2,799,370

​

$

34.21

​

—

Exercised

 

(66,830)

​

$

27.46

​

—

Canceled

 

(291,169)

​

$

41.05

​

—

Options outstanding at September 30, 2026

 

11,575,649

​

$

27.98

​

7.2

Options vested and expected to vest at September 30, 2026

 

11,364,937

​

$

27.93

​

7.2

Options exercisable at September 30, 2026

 

6,458,473

​

$

25.75

​

5.8

Shares available for grant under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 25, 2026) at September 30, 2026

 

3,516,635

​

​

​

​

​

​

The weighted average grant-date fair value of stock options granted during the three and nine months ended September 30, 2026 was $23.84 and $21.12, respectively.

The aggregate intrinsic value of stock options vested and expected to vest at September 30, 2026 was $69.7 million. The aggregate intrinsic value of stock options exercisable at September 30, 2026 was $53.0 million. As of September 30, 2026, total compensation cost related to non-vested employee, consultant and non-employee director stock options not yet recognized was approximately $92.3 million, net of estimated forfeitures, which is expected to be recognized as expense over a weighted average period of 2.8 years.

Stock-based compensation expense for the three and nine months ended September 30, 2026 and 2025 was recorded as follows:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30,

​

Nine Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

(In thousands)

​

(In thousands)

Research and development

​

$

5,626

​

$

4,743

​

$

14,861

​

$

14,210

General and administrative

​

 

5,348

​

 

4,058

​

 

13,044

​

 

13,098

Total stock-based compensation expense

​

$

10,974

​

$

8,801

​

$

27,905

​

$

27,308

​

The fair values of employee, consultant and non-employee director stock options granted during the three and nine months ended September 30, 2026 and 2025 were valued using the Black-Scholes option pricing model with the following assumptions:

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30,

​

Nine Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Expected stock price volatility

 

62 – 63%

​

76%

​

62 – 76%

​

76 – 81%

Expected option term

 

6.0 Years

​

6.0 Years

​

6.0 Years

​

6.0 Years

Risk-free interest rate

 

4.3 – 4.9%

​

4.0 – 4.2%

​

3.8 – 4.9%

​

4.0 – 4.7%

Expected dividend yield

 

None

​

None

​

None

​

None

​